[1]
Iliadis F, Kadoglou N, Didangelos T. Insulin and the heart. Diabetes Res Clin Pract 2011; 93(Suppl. 1): S86-91.
[2]
Karamitsos DT. Antiatheromatic effects of insulin. Diabetes Res Clin Pract 2011; 93(Suppl. 1): S105-8.
[3]
Gilbert RE, Krum H. Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 2015; 385: 2107-17.
[4]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
[5]
Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168-74.
[6]
Herman ME, O’Keefe JH, Bell DSH, et al. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis 2017; 60: 422-34.
[7]
Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999; 20: 789-95.
[8]
Bauters C, Lamblin N, Mc Fadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2: 1.
[9]
McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-51.
[10]
Bell DS. Heart failure: The frequent, forgotten and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-41.
[11]
Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
[12]
De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004; 25: 656-62.
[13]
Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 1994; 17: 633-9.
[14]
Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011; 378: 140-6.
[15]
Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
[16]
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. The Am J Cardiol 1974; 34: 29-34.
[17]
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-12.
[18]
Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: The MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51: 1775-83.
[19]
Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943-9.
[20]
van den Berge JC, Constantinescu AA, Boiten HJ, et al. Short- and long-term prognosis of patients with acute heart failure with and without diabetes: Changes over the last three decades. Diabetes Care 2018; 41: 143-9.
[21]
Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 1999; 353: 617-22.
[22]
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The 2003; 348: 383-93.
[23]
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
[24]
Oellgaard J, Gaede P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018; 61: 1724-33.
[25]
Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298-307.
[26]
de Jong M, van der Worp HB, van der Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 2017; 16: 134.
[27]
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
[28]
Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PRO-active study (PROactive 08). Diabetes Care 2007; 30: 2773-8.
[29]
Packer M. worsening heart failure during the use of DPP-4 Inhibitors: Pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. JACC Heart Fail 2018; 6: 445-51.
[30]
Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose co-transporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: A systematic review and meta-analysis of cardiovascular outcomes trials. Circulartion 2019; 139(17): 2022-31.
[31]
Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 Inhibitors and cardiovascular risk: Lessons learned From the EMPA-REG OUTCOME study. Diabetes Care 2016; 39: 717-25.
[32]
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752-72.
[33]
Tanaka A, Node K. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol 2017; 69: 501-7.
[34]
Poulsen MK, Henriksen JE, Dahl J, et al. Left ventricular diastolic function in type 2 diabetes mellitus: Prevalence and association with myocardial and vascular disease. Circ Cardiovasc Imaging 2010; 3: 24-31.
[35]
Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007; 49: 1696-704.
[36]
Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs. glyburide in early heart failure: Insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 2010; 16: 111-7.
[37]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-57.
[38]
Didangelos TP, Arsos G, Karamitsos T, et al. Left ventricular systolic and diastolic function in normotensive type 2 diabetic patients with or without autonomic neuropathy: A radionuclide ventriculography study. Angiology 2014; 65: 877-82.
[39]
Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2016; 90: 84-93.
[40]
Boudina S, Abel ED. Mitochondrial uncoupling: A key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 2006; 21: 250-8.
[41]
Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: Direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56: 2457-66.
[42]
How OJ, Aasum E, Severson DL, et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55: 466-73.
[43]
Goldberg IJ. 2017 George lyman duff memorial lecture: Fat in the blood, fat in the artery, fat in the heart: Triglyceride in physiology and disease. Arterioscler Thromb Vasc Biol 2018; 38: 700-6.
[44]
Laakso M. Heart in diabetes: A microvascular disease. Diabetes Care 2011; 34(Suppl. 2): S145-9.
[45]
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res 2018; 122: 624-38.
[46]
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.
[47]
Fukuda K, Kanazawa H, Aizawa Y, et al. Cardiac innervation and sudden cardiac death. Circ Res 2015; 116: 2005-19.
[48]
Rennings AJ, Smits P, Stewart MW, et al. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: A randomised, controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 2010; 53: 1856-66.
[49]
Pfeifer MA, Weinberg CR, Cook DL, et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984; 7: 447-53.
[50]
Chaudhary AK, Aneja GK, Shukla S, et al. Study on diastolic dysfunction in newly diagnosed type 2 diabetes mellitus and its correlation with glycosylated haemoglobin (HbA1C). J Clin Diagn Res 2015; 9: 20-2.
[51]
Nakai H, Takeuchi M, Nishikage T, et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: Correlation with diabetic duration. Eur J Echocardiogr 2009; 10: 926-32.
[52]
Ernande L, Bergerot C, Rietzschel ER, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: Is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 2011; 24: 1268-75.e1.
[53]
Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9.
[54]
Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
[55]
Lautamaki R, Airaksinen KE, Seppanen M, et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes 2006; 55: 511-6.
[56]
Su H, Sun X, Ma H, et al. Acute hyperglycemia exacerbates myocardial ischemia/reperfusion injury and blunts cardioprotective effect of GIK. Am J Physiol Endocrinol Metab 2007; 293: E629-35.
[57]
Bertrand L, Horman S, Beauloye C, et al. Insulin signalling in the heart. Cardiovasc Res 2008; 79: 238-48.
[58]
Manhiani MM, Duggan AD, Wilson H, et al. Chronic intrarenal insulin replacement reverses diabetes mellitus-induced natriuresis and diuresis. Hypertension 2012; 59: 421-30.
[59]
Irsik DL, Chen JK, Brands MW. Chronic renal artery insulin infusion increases mean arterial pressure in male Sprague-Dawley rats. Am J Physiol Renal Physiol 2018; 314: 81-8.
[60]
Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 303: R1101-9.
[61]
Hall JE, Brands MW, Kivlighn SD, et al. Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines? Hypertension 1990; 15: 519-27.
[62]
Hall JE, Coleman TG, Mizelle HL, et al. Chronic hyperinsulinemia and blood pressure regulation. Am J Physiol 1990; 258: F722-31.
[63]
Pontiroli AE, Alberetto M, Pozza G. Patients with insulinoma show insulin resistance in the absence of arterial hypertension. Diabetologia 1992; 35: 294-5.
[64]
Khunti K, Damci T, Meneghini L, et al. Study of Once Daily Levemir (SOLVE): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 2012; 14: 654-61.
[65]
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28.
[66]
Nielsen R, Wiggers H, Thomsen HH, et al. Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: A randomized study. BMJ Open Diabetes Res Care 2016; 4: e000202
